<DOC>
	<DOCNO>NCT01202799</DOCNO>
	<brief_summary>It anticipate PENNSAID Gel minimize systemic exposure versus oral diclofenac administer twice day ( BID ) . In addition , PENNSAID Gel result great subject convenience compliance comparable bioavailability , safety tolerability profile approve PENNSAID solution administer four time day ( QID ) .</brief_summary>
	<brief_title>Pharmacokinetics , Bioavailability Safety PENNSAID® Gel</brief_title>
	<detailed_description>PENNSAID Gel new topical gel formulation diclofenac sodium similar composition PENNSAID solution . No clinical study conduct use PENNSAID Gel . The current study compare pharmacokinetics , bioavailability , safety tolerability diclofenac topical application PENNSAID Gel approve formulation topical PENNSAID Solution oral Sandoz 75 mg diclofenac sodium delay release tablet healthy subject . The efficacy profile PENNSAID Gel base know efficacy profile PENNSAID solution . Support BID dose regimen include high concentration diclofenac sodium PENNSAID Gel ( 2.0 % ) compare PENNSAID solution ( 1.5 % ) . In addition , compare PENNSAID solution , PENNSAID Gel design good penetration diclofenac allow reduction number application per day four two maintain effectiveness .</detailed_description>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<criteria>The eligibility subject enter study base meeting inclusion criterion list : 1 . Signed dated IRB approve consent protocol procedure perform . 2 . Males nonpregnant , nonlactating female , minimum 18 year age maximum 55 year age . 3 . Female subject must negative serum pregnancy test , postmenopausal least 1 year , surgically sterile , use acceptable form contraception 30 day prior dose duration study participation . 4 . Subjects body mass index ( BMI ) ≥19 ≤29 kg/m² . 5 . The finding ECG interpretation must within normal range . 6 . Subjects whose health status assess investigator `` normal healthy '' require screening checkin assessment . 7 . Subjects must able provide write consent agree comply study requirement . Subjects ineligible study meet follow criterion : 1 . Known hypersensitivity diclofenac , aspirin [ acetylsalicylic acid ( ASA ) ] NSAID , dimethyl sulfoxide ( DMSO ) ethanol . This include subject exhibit aspirin NSAIDinduced symptom , include bronchospasm , rhinitis , urticaria NSAIDinduced allergic symptom . 2 . Pregnant lactating woman . Women reproductive potential ( woman &lt; 12 month menopause ) may participate unless agree use effective contraceptive method study . 3 . Evidence serious active infection , severe uncontrolled cardiac , renal , hepatic , pulmonary systemic disease , significant medical psychiatric illness , know seropositivity HIV , know unexplained vision change , history unexplained syncope , lightheadedness , high blood pressure , chronic hepatic condition like hepatic porphyria clinically significant laboratory finding would , investigator judgment , make subject inappropriate study . 4 . Documented ( upper GI series endoscopy ) gastroduodenal ulcer GI bleeding ( except hemorrhoidal ) within last 6 month prior screen . 5 . Abnormal hepatic renal function ; hematologic change : Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≥2.5 X ULN Gammaglutamyl transpeptidase ( GGT ) ≥3X ULN Total bilirubin ≥1.5X ULN Serum creatinine ≥1.5X ULN Hemoglobin ≤LLN . 6 . Major surgery previous damage study knee ( ) time ( eg . total knee replacement , damage/reconstruction anterior posterior cruciate ligament ) , minor knee surgery ( eg , cartilage repair , collateral ligament repair , arthroscopic debridement ) study knee ( ) within 1 year prior screen . 7 . Administration sedative hypnotic medication insomnia within 14 day prior screen . 8 . Administration antidepressant , within 60 day prior screen . 9 . Administration another investigational drug within previous 30 day prior screen . 10 . Skin disorder affect palm hand application site knee ( ) . 11 . History chronic headache . 12 . Documented history alcohol drug abuse within 1 year prior screen visit 13 . Subjects smoke use nicotinecontaining product within 6 month prior Period 1 dosing . 14 . Subjects treat systemic local diclofenac within one month study Day 1 . 15 . Using artificial exposure , tan bed , selftanning cream knee area within 90 day study start . 16 . Donation significant loss blood ( 480 mL ) within 30 day dose . 17 . Previous participation study participation another clinical trial within 30 day prior screen . 18 . Noncompliance study protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Healthy volunteer</keyword>
	<keyword>PENNSAID</keyword>
	<keyword>Topical NSAID</keyword>
	<keyword>Diclofenac</keyword>
</DOC>